A RANDOMIZED CONTROLLED TRIAL OF TWO SCHEDULES OF HEPATITIS B VACCINATION IN PREDIALYSED CHRONIC RENAL FAILURE PATIENTS

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

AHMADI FAROKHLAGHA; RAMEZANI MORTEZA; RAZEGHI EFFAT; RANJBARNOVIN NEDA; KHAZAEIPOUR ZAHRA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Hepatitis Monthly Year:2012 | Volume:12 | Issue:5 Page(s): 344-348

Download Full-Text

View:

267

Download:

210

Cites:

Information Journal Paper

Title

A RANDOMIZED CONTROLLED TRIAL OF TWO SCHEDULES OF HEPATITIS B VACCINATION IN PREDIALYSED CHRONIC RENAL FAILURE PATIENTS

Author(s)

Keywords

KIDNEY FAILURE

CHRONIC

HEPATITIS B

VACCINATION

Abstract

Background: Patients with CHRONIC renal disease should be vaccinated as soon as dialysis is forestalled, and this could improve the seroconversion of HEPATITIS B VACCINATION. Objectives: In this study, we aimed to compare seroconversion and immune response rates using 4 doses of 40 mg and 3 doses of 20 mg Euvax B recombinant HEPATITIS B surface Antigen (HBs Ag) vaccine administered to predialysis patients with CHRONIC kidney disease (CKD). Patients and Methods: In an open, randomized clinical trial, we compared seroconversion rates in 51 predialysis patients with mild and moderate CHRONIC renal failure who received either 4 doses of 40 mg or 3 doses of 20 mg of Euvax B recombinant HEPATITIS B vaccine administered at 0, 1, 2, 6 and 0, 1, 6 months, respectively.Results: Differences in seroconversion rates after 4 doses of 40 mg (80.88%) compared to 3 doses of 20 mg (92%) were not significant (P = 0.4124). The mean HBs antibody level after 4 doses of 40 mg at 0, 1, 2, and 6 months (182.2 ± 286.7) was significantly higher than that after 3 doses of 40 mg at 0,1, and 6 months (96.9 ± 192.1) (P = 0.004). Seroconversion after 4 doses of 40 mg (80.8%) was also significantly higher than that after 3 doses of 40 mg (77%) (P = 0.004). Multivariable analysis showed that none of the variables contributed to seroconversion.Conclusions: We found that 4 doses of 40 mg did not lead to significantly more seroconversion than 3 doses of 20 mg.

Cites

No record.

References

No record.

Cite

APA: Copy

AHMADI, FAROKHLAGHA, RAMEZANI, MORTEZA, RAZEGHI, EFFAT, RANJBARNOVIN, NEDA, & KHAZAEIPOUR, ZAHRA. (2012). A RANDOMIZED CONTROLLED TRIAL OF TWO SCHEDULES OF HEPATITIS B VACCINATION IN PREDIALYSED CHRONIC RENAL FAILURE PATIENTS. HEPATITIS MONTHLY, 12(5), 344-348. SID. https://sid.ir/paper/306528/en

Vancouver: Copy

AHMADI FAROKHLAGHA, RAMEZANI MORTEZA, RAZEGHI EFFAT, RANJBARNOVIN NEDA, KHAZAEIPOUR ZAHRA. A RANDOMIZED CONTROLLED TRIAL OF TWO SCHEDULES OF HEPATITIS B VACCINATION IN PREDIALYSED CHRONIC RENAL FAILURE PATIENTS. HEPATITIS MONTHLY[Internet]. 2012;12(5):344-348. Available from: https://sid.ir/paper/306528/en

IEEE: Copy

FAROKHLAGHA AHMADI, MORTEZA RAMEZANI, EFFAT RAZEGHI, NEDA RANJBARNOVIN, and ZAHRA KHAZAEIPOUR, “A RANDOMIZED CONTROLLED TRIAL OF TWO SCHEDULES OF HEPATITIS B VACCINATION IN PREDIALYSED CHRONIC RENAL FAILURE PATIENTS,” HEPATITIS MONTHLY, vol. 12, no. 5, pp. 344–348, 2012, [Online]. Available: https://sid.ir/paper/306528/en

Related Journal Papers

No record.

Related Seminar Papers

No record.

Related Plans

No record.

Recommended Workshops